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Abstract
Mitochondria are the places for the energy production of the cells, while reac-
tive oxygen species (ROS) are also produced alongside. In recent years, it has 
been reported that cancer stem cells metabolize predominantly through oxidative 
phosphorylation (OXPHOS) rather than glycolysis. Targeting OXPHOS achieved 
by suppression of ATP synthesis through mitochondrial ATP synthase could be a 
potential therapeutic option against cancer stem cells. Since c-Myc inhibition is 
considered to lead a metabolic flux to OXPHOS from glycolysis, the combinatory 
inhibition of both OXPHOS and glycolysis could be a strong candidate for the treat-
ment of malignant tumors. In this chapter, we will discuss about the mitochondria 
metabolism as the potential therapeutic target in osteosarcoma stem cells, and 
the synergistic effects of combination of OXPHOS inhibitor with c-Myc inhibitor, 
which target both OXPHOS-dominant cancer stem cells and glycolysis-dominant 
non-cancer stem cells, will be discussed.
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1. Introduction
Intratumor heterogeneity, which is the basis of tumor evolution, is the funda-
mental challenge in cancer medicine. Intratumor heterogeneity is considered to 
be involved in several important aspects in cancer biology such as disease relapse 
and metastatic behaviors as well as drug resistance. Over the past decades, a small 
subset of tumor cells, so-called cancer stem cells (CSCs), have been proposed to be 
a hierarchical organizer of the tumor heterogeneity [1] and play a critical role in 
tumor relapse, metastasis, drug resistance, and tumor propagation in many cancer 
types including osteosarcoma (OS) [2–6]. At the apex of the heterogeneity in the 
tumor, CSCs possess the capacity of self-renew and tumorigenicity which generate 
the bulk of tumor with more differentiated progenies [7]. Conventional anticancer 
therapies target the bulk of heterogeneous tumor mass resulting in tumor shrink-
age, but CSCs could trigger the relapse by differentiation into non-stem tumor cells. 
Thus, targeting CSCs could represent an integral component for developing more 
effective treatment strategies against cancer.
Now, we have evidences that cancer heterogeneity not only is generated by 
genetically distinct subclones but is also driven by phenotypic and functional 
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heterogeneity within each subclone [8, 9]. One of the distinct phenotypes of CSCs is 
their cellular metabolism mechanisms for energy production. Tumor cells repro-
gram their metabolic machinery to meet their needs during tumor growth known as 
Warburg effect which shifts their ATP production from via oxidative phosphoryla-
tion (OXPHOS) to glycolysis even in the microenvironment with abundant oxygen 
concentration [10]. Over the past years, the metabolic phenotype of CSCs has 
been intensely investigated, and it was originally hypothesized that CSCs would 
reflect the normal tissue hierarchy where multipotent stem cells are fundamentally 
glycolytic, while differentiated somatic cells rely on OXPHOS [11]. Although 
the differentiated cells increase their dependency upon the glycolysis during the 
acquisition of the transformed phenotype, these changes might be cell specific, and 
some cells might adapt to neoplastic transformation by increasing their dependency 
on OXPHOS [12]. As a matter of fact, the metabolic phenotype of CSCs are con-
troversial suggesting that it could be a tumor-type- or cell line-dependent manner 
such as breast and nasopharyngeal CSCs relying on glycolysis [13, 14], while lung, 
glioblastoma and pancreatic ductal adenocarcinoma CSCs relying on OXSPHOS 
[15–17]. In osteosarcoma (OS), a CSC-like cell line, 3AB-OS, exhibited its metabolic 
dependency on glycolysis compared to the parental MG-63 cells [18]. However, this 
came from only one cell line chemically treated long time from MG-63 which bore 
the ras gene mutation unusually found in OS. Controversially, there is the evidence 
that the transformed mesenchymal stem cells (MSCs), which are supposed to be the 
sarcoma-initiating cells or sarcoma stem cells, showed the increased OXPHOS and 
had a capability to switch to glycolysis to adapt to their microenvironments [19]. 
The discrepancy in these metabolic profiles of CSCs would be due to multifactorial 
causes. The first possible explanation is the plasticity of these cells in response to the 
microenvironment and the stages of harvesting in terms of differentiation/dedif-
ferentiation [20]. Another possible cause would be the lack of precise definition of 
CSCs and their heterogeneity due to the various techniques for CSC isolation [21]. 
Furthermore, the metabolic status of CSCs can be affected by cross talk between 
CSCs and cancer-associated stroma in the microenvironment. For instance, OS cells 
directly increase their mitochondrial biogenesis using this energy-rich metabolite 
such as lactate that is abundantly provided by MSC as an effect of the altered 
microenvironmental conditions induced by OS cells, and the lactate produced by 
MSC promotes the migratory ability of OS cell [22].
Actually, there are several reports indicating that CSCs have augmented utiliza-
tion of extracellular catabolites such as pyruvate, lactate to support OXPHOS, [23] 
and mitochondrial metabolism could be a potential target for an effective elimina-
tion of CSCs [17]. Previous studies suggested that inhibition of the OXPHOS path-
way reduced sphere formation and tumor formation capacity, which demonstrated 
the vulnerability of CSCs to mitochondria-targeted therapies [24], and several 
agents such as salinomycin targeting CSCs through inhibition of mitochondrial bio-
genesis and OXPHOS are currently under investigation for cancer treatment [25].
Here, we will discuss about the mitochondrial metabolism as a potential thera-
peutic target in osteosarcoma, especially its stem-like cell populations.
2. Myc is a key regulator of cancer cell metabolism
Glucose is one of the major nutrients that mammalian cells utilize to synthe-
size new organelles as well as to generate high-energy molecules, such as ATP, 
NADH/NADPH, and FADH. c-Myc played an important role in regulation of 
glycolysis through its target glucose metabolism genes [26], and those genes 
directly regulated by c-Myc include glucose transporter GLUT1, hexokinase 2 
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(HK2), phosphofructokinase (PFKM), and enolase 1 (ENO1) [27, 28].  Myc was 
also observed to upregulate lactate dehydrogenase A (LDHA) to generate NAD+, 
which is a cofactor required for the glycolysis particularly by GAPDH [29]. Through 
the upregulation of these genes, c-Myc contributes directly to the Warburg effect 
(aerobic glycolysis) and the ability of transformed cells to convert glucose to 
pyruvate even under adequate oxygen tension. Myc also regulates protein synthesis, 
ribosome biogenesis, nucleotide biosynthesis, as well as fatty acid and cholesterol 
metabolism. Cancer cells take advantage of these Myc’s broad reaches to reprogram 
and augment the most critical processes for survival, particularly metabolism.
In addition to the metabolic reprogramming, c-Myc also contributes to the cell 
cycle regulation in corporation with PI3K (phosphatidylinositol-3,4,5-triphos-
phate)/Akt/mTOR (mammalian target of rapamycin) and Wnt pathway. The role 
of PI3K-Akt-mTOR and Wnt pathways in regulation of the cell cycle progression 
in cancer cell has been proposed (Figure 1). The activation of insulin/insulin-like 
growth factor (IGF) receptor by nutrients/growth factors activates PI3K-Akt path-
way. The phosphorylated Akt activates mammalian target of rapamycin complex 1 
(mTORC1), and the activated mTORC1 upregulates the protein synthesis but inhib-
its autophagy. Inhibition of autophagy rescues Dvl (Dish homolog in mammalian), 
and this leads to activation of Wnt pathway. Wnt pathway is the key pathway in 
activation of cell cycle, and the activated Wnt pathway upregulates the CyclinD; the 
c-Myc; the matrix metalloproteinases, COX-2, peroxisome proliferator-activated 
receptors (PPARs); and the growth factors and their receptors and downregulates 
E-cadherin, the cell cycle inhibitor p16INK4a (ARF), and p53 [30]. Wnt pathway 
thus regulates the cancer cell entry into the cell cycle through the production of 
Figure 1. 
c-Myc contributes to the cell cycle regulation in corporation with PI3K/Akt/mTOR and Wnt pathway. The 
activation of insulin/IGF receptor by nutrients/growth factors activates PI3K-Akt pathway. The phosphorylated 
Akt activates mTORC1, which eventually leads to activation of Wnt pathway. Wnt pathway is the key 
pathway in activation of cell cycle, and the activated Wnt pathway upregulates the CyclinD, the c-Myc which 
would be involved in tumor initiation as well as tumor progression.
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CyclinD. CyclinD complexes with cyclin-dependent kinase 4/6 (Cdk4/6), inacti-
vates the tumor suppressor protein retinoblastoma (Rb), and promotes the entry 
of the cell from G0 to G1 phase of cell cycle as well as metabolic reprogramming 
through the c-Myc activation as described above. In this context, c-Myc is acknowl-
edged to play an important role to activate genes involved in predominantly cell 
cycle regulation, cellular metabolism, and protein synthesis, especially specific to 
G0-G-S transition as well as glycolysis and Krebs cycle, chromatin structure, and its 
transcriptional networks in cancer cells and embryonic stem cells as well [31, 32]. 
Given its crucial role in cancer progression and maintenance, c-Myc has been the 
ideal target for cancer therapy, and c-Myc targeting strategy in cancer therapy has 
been investigated in various means such as direct inhibition by antisense oligonucle-
otide [33] and siRNA [34], indirect inhibition by blocking transcription with BET 
bromodomain inhibitors such as JQ-1 [35], and blocking mRNA translation with 
mTOR inhibitor [36]. After a long time struggling on targeting c-Myc in cancer 
therapy, we are now witnessing a renewed interest in making Myc inhibition for 
the future cancer therapy. In the aspect of c-Myc contribution to the metabolism, 
c-Myc promotes a Warburg-like glycolytic phenotype through dual mechanism 
of upregulation of key glycolytic enzymes as described above, and suppression of 
peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) 
by direct inhibition through binding to its promoter [17]. PGC-1α is crucial for the 
anti-oxidative capacity and mitochondrial metabolism in cancer [37, 38] and con-
tributes to the maintenance of CSC’s phenotype of self-renewal through controlling 
intracellular ROS levels. Myc/PGC-1α balance controls the metabolic phenotype 
of cancer cells as c-Myc dominance shifts to Warburg phenotype of differentiated 
cancer cells and PGC-1α dominance shifts to OXPHOS-dependent phenotype of 
CSCs [17]. Therefore, combining OXPHOS inhibition with c-Myc inhibition could 
provide a new multimodal approach for targeting the distinct metabolic features in 
cancer therapy.
3. Cancer stem cell metabolism: a potential therapeutic target
CSCs also known as tumor-initiating cells (TICs) are a rare population of tumor 
cells with stem cell properties, which are thought to generate the tumor bulk and 
considered to drive the malignant growth, treatment resistance, minimal residual 
disease, and metastases. Along with the role of cancer drivers, CSCs also exhibit 
stem cell properties such as self-renewal and multilineage differentiation capacity 
[39]. CSCs are considered to be resistant to chemotherapy or radiations, both of 
which successfully destroy differentiated non stem-like cancer cells. As a matter of 
fact, even though current conventional anticancer therapies could achieve a tran-
sient control over the disease, a large number of patients experience tumor relapse 
or metastatic dissemination after an initial treatment with apparent disease-free 
period. Since CSCs, resisting to conventional therapies, attributes these biological 
behaviors, eradication of CSCs could be a promising target to totally exterminate 
the disease of cancer [40].
Although much is known regarding metabolic pathways important for cancer 
cell survival, the potential for therapeutic metabolic alteration of CSCs has not been 
fully uncovered [41], but recent studies indicate that metabolism and stemness are 
highly intertwined processes in tumor tissues, and CSCs possibly have different 
metabolic properties compared to non-CSCs.
Glucose homeostasis is reciprocally controlled by the catabolic glycolysis/
OXPHOS and by the anabolic gluconeogenesis pathway. In the catabolic reaction, 
when oxygen is absent, glycolysis predominantly controls the metabolism of ATP 
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production, while in the presence of oxygen, OXPHOS predominantly regulates 
the maximal ATP production in the mitochondria. Cancer cells preferentially 
metabolize glucose rather than OXPHOS even in the presence of oxygen defined 
as Warburg effect/aerobic glycolysis by the activation of some key genes such as 
c-Myc. In contrast to the somatic cells which primarily utilize OXPHOS, pluripotent 
stem cells including embryonal stem cells and induced pluripotent stem cells rely 
on glycolysis [42]. Therefore, it has to be pointed out that the biological functions 
of CSCs are different from those of differentiated cancer cells, making their pheno-
type more similar to normal stem cell, and metabolism is not the exception. Since 
aerobic glycolysis/Warburg effect has been widely accepted and recognized as a 
peculiar hallmark of cancer cells, it may be reasonable to expect that, conversely, 
CSC metabolism is mostly oriented toward mitochondrial OXPHOS. Actually, it is 
broadly accepted that ATP production in CSCs depends on glycolysis or OXPHOS in 
a tumor-type-dependent manner. The heterogeneity and plasticity of CSCs prob-
ably determine their primary source of energy to survive. The recent investigation 
has suggested that CSCs may display a broader repertoire of biochemical behavior 
in response to different environmental conditions, and accumulating evidence has 
indicated that CSCs utilize OXPHOS not only relying on the glycolysis [41, 43]. CSC 
metabolism show a highly plastic profile which allows to fulfill the energy require-
ments, according to the most suitable environmental condition. This metabolic 
flexibility of CSCs has been shown in diverse tumor types demonstrating that CSCs 
efficiently gain energy production from glycolysis when OXPHOS is blocked [44]. 
Recently, De Francesco et al. proposed the “two metabolic hit strategies” for eradi-
cation of CSCs (Figure 2) [45]. They demonstrated that the prolonged treatment 
with a mitochondria-interfering agent like doxycycline drastically impairs oxygen 
consumption rate (OCR) and mitochondrial respiration in MCF7 breast cancer 
cells. Such impairment in mitochondrial activity represents a first metabolic hit that 
constrains cellular metabolism of the surviving cancer cell subpopulation toward a 
Figure 2. 
The treatment with a mitochondria-interfering agent impairs oxygen consumption rate (OCR) and 
mitochondrial respiration in cancer cells as a metabolic first hit that constrains cellular metabolism of the 
surviving cancer cell subpopulation toward a predominantly glycolytic phenotype, resulting in metabolic 
inflexibility, as evidenced by the increased extracellular acidification rate (ECAR). The use of a glycolysis 
inhibitor may therefore act as the second metabolic hit that efficiently targets CSCs by halting their biochemical 
machinery (X axis, time (min); Y axis, pmoles/min/mg protein; red line, mitochondria inhibitor treatment; 
blue line, control).
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predominantly glycolytic phenotype, resulting in metabolic inflexibility, as evi-
denced by the increased extracellular acidification rate (ECAR). In this sequence, 
the glycolysis inhibitor potentially acts a second metabolic hit which effectively 
targets CSCs. Thus, specific metabolic-oriented pharmacological intervention 
could reverse CSC metabolic plasticity toward an inflexible biochemical phenotype, 
representing a new synthetic-lethal metabolic strategy for eradicating CSCs.
4. Targeting mitochondrial physiology in cancer stem cells
Mitochondria are key organelles involved in several processes related to cell 
proliferation and survival, and their most important function is the generation of 
ATP which holds cell metabolism. As the main energy producers, mitochondria 
produce ATP using tricarboxylic acid (TCA) cycle and OXPHOS. They also generate 
reactive oxygen species (ROS) during this process, which are sometimes harmful to 
the cells when produced excessively.
Because mitochondria play a key role in the alteration of oxidative stress and 
energy status, their functional characteristics have been considered to verify stemness 
like stem cell stability and pluripotency [46, 47]. Mitochondrial metabolic activity 
and antioxidant enzyme expression have shown to be closely related to the cell differ-
entiation [48, 49]. Thus, we could assume that stem cell mitochondria play important 
roles in maintaining stemness and differentiation. However, whether the roles of CSC 
mitochondria are similar to stem cell mitochondria or so-called differentiated cancer 
cells in general is not clear. Based on the previous reports, the CSCs might be more 
differentiated than normal stem cells, and the mitochondrial properties of CSCs are 
possibly different from those of stem cells or general cancer cells [39, 50].
Mitochondria have a multi-level network of antioxidant and OXPHOS systems 
(Figure 3). Mitochondrial redox balances are regulated by the mitochondrial 
inner membrane electrochemical gradient. As shown in Figure 3, nicotinamide 
adenine dinucleotide (NADH) from TCA cycle is oxidized by Complex I in the 
electron transport chain (ETC) of OXPHOS. Electrons from Complex I and II are 
Figure 3. 
Mitochondrial redox balances are regulated by the mitochondrial inner membrane electrochemical gradient. 
NADH from TCA cycle is oxidized by Complex I in the ETC. Electrons from Complex I and II are transferred 
to coenzyme Q10 and then passed on to Complex III, cytochrome c, Complex IV, and finally O2 to generate 
H2O. Complex V (F0F1-ATP synthase) generates ATP from ADP for the cellular energy source.
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transferred to coenzyme Q10 and then passed on to Complex III, cytochrome c, 
Complex IV, and finally O2 to generate H2O. Complex V (ATP synthase; F0-F1) 
generates ATP from ADP as well as inorganic phosphate Pi.
A powerful strategy focused on mitochondrial biogenetics as a target to eradi-
cate CSCs involves inhibition of the ETC complex, with consequent ROS overpro-
duction. Dong et al. demonstrated that the suppression of mitochondrial Complex 
I activity inhibited oxygen consumption and induced glycolysis in breast CSCs as a 
result of loss of fructose-1,6-biphosphatase implying that overproduction of ROS 
and reduction in glucose metabolism might be effective against breast CSCs [11]. 
Hirsch et al. also showed that metformin, the first-line antidiabetic drug, selectively 
killed the CSCs in breast cancer cell line through the inhibition of Complex I [51]. 
Furthermore, atovaquone, an FDA-approved antimalarial drug, inhibits the propa-
gation of breast cancer cell line MCF7-derived CSCs through the selective OXPHOS 
inhibition by targeting the CoQ10 dependence of mitochondrial Complex III [52]. 
This has been explored in the context of therapy as indicated by Alvero et al. using 
the novel isoflavone derivative NV-128 which significantly decreased mitochondrial 
function, as shown by a decrease in ATP, Complex I and Complex IV levels, and 
induced cell death in ovarian CSCs [53]. Finally, mitochondria-targeted vitamin 
E succinate (MitoVES) has been well characterized as an agent, which potentiates 
the ability to induce apoptosis in breast CSCs [54]. Reduction of mitochondrial 
membrane potential, overproduction of mitochondrial ROS, and inhibition of 
mitochondrial biogenesis have been demonstrated to affect CSC proliferation 
and survival [55]. These inputs indicate that the maintenance of CSC prolifera-
tion may not only be dependent on glycolysis, but is also based on mitochondrial 
activity. Therefore, the specific mitochondrial-targeted compounds which induce 
cell death in chemoresistant CSCs are promising novel therapeutic venue to treat 
cancer patients with relapsed or metastatic diseases. The most important point is 
that mitochondria from CSCs are not indistinguishable to those from differentiated 
non stem-like tumor cells in divergent aspects. Since CSCs are considered to be 
heterogeneous and adaptive metabolic profiles, the future therapy targeting cellular 
metabolism should be designed in a form of simultaneous or selective blockade of 
both glycolysis and mitochondrial respiration to completely eradicate CSCs [20]. 
Consequently, dual inhibition of glycolytic and mitochondrial energy pathways 
has proven to be effective against tumor growth in a number of preclinical cancer 
models. For instance, dual inhibition of glycolysis by 2-deoxyglucose (2-DG) and 
OXPHOS by metformin is effective in vivo against breast cancer cell xenograft 
model [56]. However, hexokinase inhibitors such as 2-DG and 3-bromopyruvate 
have been unfortunately discontinued in clinical trials. There has been an elegant 
study demonstrating sarcoma cells to be more sensitive than normal cells to dual 
inhibition of glycolysis with 2-deoxyglucose and OXPHOS with oligomycin or met-
formin [57]. Recently, Kang et al. have demonstrated that ALDH inhibitor gossypol 
combined with mitochondrial Complex I inhibitor phenformin resulted in up to 
80% ATP depletion in non-small cell lung cancer, which induced significant tumor 
regression in the cancer xenograft model [58]. These warrant that a key molecule 
regulating cancer energy metabolism can be a therapeutic target.
Meanwhile, other mitochondria-related processes like activation of developmen-
tal signaling pathways including Hedgehog, Notch, and Wnt are also the druggable 
targets; the drug targeting Notch and Hedgehog pathway has been developed [59], 
and numerous molecules acting on mitochondria has been used or being tested in 
clinical trials [60]. Adding these attempts targeting mitochondria, we will empha-
size that the dual inhibition of metabolic pathways could be an approach with 
greater potential to eradicate heterogeneous CSCs rather than singularly targeting 
glycolysis or OXPHOS pathway.
Osteosarcoma – Diagnosis, Mechanisms, and Translational Developments
8
5. Novel approach to target cellular metabolism in osteosarcoma
Osteosarcoma and mitochondria have been investigated since 1970; however, 
those are mostly limited to the morphological characteristics by microscopic or 
electron microscopic observation [61, 62].
Giang et al. demonstrated that highly invasive and metastatic cell lines were 
more relied on Warburg effect-like glycolysis than their parental cell lines which 
showed similar mitochondrial oxygen consumption rate to fetal osteoblasts, sug-
gesting that highly metastatic and invasive cell lines were in the state of suppression 
of mitochondrial function and upregulation of glycolysis. They suggested that the 
mechanism of mitochondrial dysfunction was the results of mitochondrial perme-
ability transition such as mitochondrial swelling, depolarization, and membrane 
permeabilization, and they also demonstrated that this mitochondrial dysfunc-
tion and the Warburg effect are reversed by the treatment with mitochondrial 
permeability transition inhibitor sanglifehrin A [63]. These results indicated that 
osteosarcoma cells might possess the metabolic plasticity in response to their 
microenvironment especially hypoxia-reoxygenation caused by an irregular blood 
supply within tumors, an immature and leaky vasculature, and an abnormal and 
constantly changing vessel network architecture.
Another biochemical mechanism which contributes to the glycolytic rate of 
tumor cells is the inhibition of mitochondrial ATP synthase (F1F0-ATPase) by the 
natural inhibitor protein IF1 [64]. Barbato et al. reported that IF1 modulates the 
mitochondrial membrane potential and oxidative phosphorylation rate in osteosar-
coma cells suggesting that interaction between IF1 and FoF1-ATPase might regulate 
the OXPHOS and glycolysis [65]. However, the detailed mechanisms regulating the 
cellular bioenergetics by IF1 have been still controversial in cancer cells under the 
complex microenvironment.
Recently, novel strategy targeting CSCs through phytochemicals and their 
analogs has been proposed, and mitochondria are one of their potential targets 
[66]. Among the various compounds, pterostilbene (PTE), which is a methyl-
ated resveratrol derived from plants, has been shown to inhibit CSC properties 
in breast cancer [67, 68], glioma [69], hepatocellular carcinoma [70], and lung 
cancer [71] through the inhibition of multiple pathways which are possibly 
related to the CSC propagation such as Wnt, Hedgehog, Notch, and PI3K/Akt. 
Honokiol (HNK), which is the extract from Magnolia obovata, has shown its 
various antitumor effects through the inhibition of several pathways such as 
PI3K/Akt/mTOR, Wnt, and c-Myc [72–74]. Besides these effects of PTE and 
HNK, we have identified that PTE in combination with HNK could be the pos-
sible metabolism-targeted therapy against osteosarcoma as a “two hit” or “dual 
inhibition” of metabolic pathways, OXPHOS and glycolysis. PTE treatment on 
human osteosarcoma cell lines SaOS2, U2OS, and MG63 reduced viabilities of 
all cell lines in dose-dependent manner, and expression of stem cell marker such 
as Oct3, NS, and CD44 and the ability of sphere formation were also decreased 
in terms of sphere number and size (Figure 4a). PTE reduced the activity of 
F0F1-ATP synthase, Complex V predominantly (Figure 4b), and the mito-
chondrial oxygen consumption rates and synthetic amount of ATP were also 
decreased in spheroid condition (Figure 4c). These results suggest that PTE 
possibly targets stem cell population which preferably relies on OXPHOS, sup-
pressing ATP synthesis via F0F1-ATP synthase inhibition as well as increased 
ROS production in osteosarcoma cells, and changes metabolic flax to glycolysis-
dependent feature.
As aforementioned before, c-Myc promotes a Warburg-like glycolytic 
phenotype through the upregulation of key glycolytic enzymes along with the 
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suppression of PGC-1α. There are several reports regarding the anticancer 
activity of HNK which is possibly associated with c-Myc as well as JQ1, a BET 
bromodomain inhibitor [74]. Thus, we conducted dual inhibition of OXPHOS by 
PTE and c-Myc inhibition by HNK or JQ1. The results showed that both of these 
agents synergistically inhibited osteosarcoma cell growth in a dose-dependent 
manner (Figure 5). Now, we are conducting an investigation of dual metabolic 
inhibition via in vivo experiments using our own established rat osteosarcoma 
model.
Figure 4. 
(a) Pterostilbene (PTE) treatment on human osteosarcoma cells reduced the ability of sphere formation in 
terms of sphere number and size. (b) PTE reduced the activity of F0F1-ATP synthase, Complex V. (c) The 
mitochondrial OCR rates and synthetic amount of ATP were also decreased in spheroid condition (Kishi et al. 
unpublished data).
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The above results suggested that c-Myc inhibitor could lead to metabolic flux to 
OXPHOS and PTE could lead to metabolic flux to glycolysis. Thus, these exerted a 
great synergistic effect with “two metabolic hits” or “dual metabolic inhibition” of 
distinct metabolic features, OXPHOS and glycolysis, and it could be a novel thera-
peutic strategy against osteosarcoma, possibly targeting both stemlike cell popula-
tion and general tumor cell population.
Figure 5. 
Dual inhibition of OXPHOS by PTE and c-Myc inhibition by Honokiol (HNK) or JQ1 showed the synergistic 
effect on inhibition of osteosarcoma cell growth in a dose-dependent manner (Kishi et al. unpublished data).
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6. Conclusions
Prognosis of the patients with osteosarcoma has been improved; actually, we 
could say “dramatically,” over the last quarter-century. However, it is also true that it 
has reached to plateau without any breakthroughs, and nearly 30% of patients still 
have to face very severe poor prognosis, especially with metastatic disease. We need 
to develop a novel treatment to combat such a poor prognostic situation. Targeting 
the distinct metabolic features of OXPHOS and glycolysis with the concept of “two 
metabolic hits”/“dual metabolic inhibition” strategy could bring a new insight into 
the field of osteosarcoma treatment, and some natural compounds such as pteros-
tilbene and honokiol could be the possible candidates to achieve this aim.
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